News Releases


Medtronic Issues $250,000 in Health Access Grants to Support Diabetes Services for the Underserved of San Antonio

December 8, 2014

SAN ANTONIO, TX - December 8, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that five San Antonio community organizations will receive a combined $250,000 in Health Access Grants in recognition of their continued commitment to promoting healthy lifestyles and improving access to healthcare, with an emphasis on diabetes. As Medtronic marks the five year anniversary of its San Antonio location, this announcement demonstrates the company's ongoing support of the local community. Medtronic Philanthropy awards Health Access Grants in 36 communities around the world where Medtronic has a major presence.

Read more >

Medtronic Begins Pivotal Study of First Predictive Low Glucose Management Technology for People with Diabetes

October 4, 2014

MINNEAPOLIS – October 4, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. The trial will evaluate the safety of its next-generation integrated insulin pump and continuous glucose monitoring (CGM) system, which automatically stops insulin delivery when the sensor measures a glucose level predicted to approach the lowest tolerable limit, and then resumes insulin delivery after those glucose levels recover. The technology is designed to help people with diabetes better manage the challenges of hypoglycemia (low blood sugar) and rebound hyperglycemia (high blood sugar) inherent in external insulin therapy use.

Read more >

People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections

July 2, 2014

MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections. While the benefits of insulin pump therapy for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Study results were published online in The Lancet today.

Read more >

Medtronic Applauds AACE/ACE on Their Updated Insulin Pump Therapy Consensus Statement

May 19, 2014

MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE:MDT) applauds the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) on their updated consensus statement on insulin pump therapy. In addition to continued support of insulin pump therapy for people with type 1 diabetes, AACE and ACE recognize the clinical value of insulin pumps in improving glucose control for those with intensively managed insulin-dependent type 2 diabetes. Improving glucose control is the key to helping people with diabetes avoid dangerous complications so that they can live fuller, healthier lives. The support of prestigious physician organizations helps ensure access to these therapies for people who need them.

Read more >

Medtronic Names Hooman Hakami Executive Vice President and Group President of the Medtronic Diabetes Group

May 13, 2014

MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the selection of Hooman Hakami as executive vice president and group president of the Medtronic Diabetes Group, the global leader in insulin pumps and continuous glucose monitoring systems. In this role, Hakami will lead Medtronic's entire global diabetes franchise, including research and development, operations, and sales and marketing.

Read more >

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Amanda Sheldon
Director of Digital Marketing and Communications

For all other media inquiries please select the appropriate Global Public and Media Relations contact